These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21348640)

  • 1. Genotyping of sex hormone-related pathways in benign and malignant human prostate tissues: data of a preliminary study.
    Balistreri CR; Caruso C; Carruba G; Miceli V; Candore G
    OMICS; 2011 Jun; 15(6):369-74. PubMed ID: 21348640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population.
    Soni A; Bansal A; Mishra AK; Batra J; Singh LC; Chakraborty A; Yadav DS; Mohanty NK; Saxena S
    Genet Test Mol Biomarkers; 2012 Aug; 16(8):835-40. PubMed ID: 22731640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of human androgens and prostatic diseases.
    Novelli G; Margiotti K; Sangiuolo F; Reichardt JK
    Pharmacogenomics; 2001 Feb; 2(1):65-72. PubMed ID: 11258198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
    Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
    Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
    [No Abstract]   [Full Text] [Related]  

  • 6. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
    Choubey VK; Sankhwar SN; Carlus SJ; Singh AN; Dalela D; Thangaraj K; Rajender S
    Asian Pac J Cancer Prev; 2015; 16(3):1033-6. PubMed ID: 25735326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
    Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
    DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genetic determinants of anatomical variants of the prostate].
    Hamadeh H; Larré S; Azzouzi AR; Cancel-Tassin G; Vallancien G; Cochand-Priollet B; Cussenot O
    Prog Urol; 2008 Apr; 18(4):214-22. PubMed ID: 18501301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Polymorphisms of hormone-related genes and prostate cancer risk in Japan].
    Watanabe M; Hirokawa Y; Shiraishi T
    Nihon Rinsho; 2005 Feb; 63(2):219-24. PubMed ID: 15714969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
    Lévesque É; Laverdière I; Lacombe L; Caron P; Rouleau M; Turcotte V; Têtu B; Fradet Y; Guillemette C
    Clin Cancer Res; 2014 Feb; 20(3):576-84. PubMed ID: 24277450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk.
    Modugno F; Weissfeld JL; Trump DL; Zmuda JM; Shea P; Cauley JA; Ferrell RE
    Clin Cancer Res; 2001 Oct; 7(10):3092-6. PubMed ID: 11595700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men.
    Izmirli M; Arikan B; Bayazit Y; Alptekin D
    Asian Pac J Cancer Prev; 2011; 12(3):731-3. PubMed ID: 21627373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
    Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
    Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.
    Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Kashiwagi B; Nishii M; Ohtake N; Nakata S; Ito K; Yamanaka H
    Cancer; 2003 Oct; 98(7):1411-6. PubMed ID: 14508827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
    Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
    Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor GGC polymorphism and testosterone levels associated with high risk of prostate cancer and benign prostatic hyperplasia.
    Biolchi V; Silva Neto B; Pianta DB; Koff WJ; Berger M; Brum IS
    Mol Biol Rep; 2013 Mar; 40(3):2749-56. PubMed ID: 23184046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
    Zambra FM; Biolchi V; Brum IS; Chies JA
    Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer].
    Liu JH; Li HW; Tong M; Li M; Na YQ
    Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):364-8. PubMed ID: 15061984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of benign prostate hyperplasia with polymorphisms in VDR, CYP17, and SRD5A2 genes among Lebanese men.
    El Ezzi AA; Zaidan WR; El-Saidi MA; Al-Ahmadieh N; Mortenson JB; Kuddus RH
    Asian Pac J Cancer Prev; 2014; 15(3):1255-62. PubMed ID: 24606449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphism in sex hormone metabolism and prostate cancer risk.
    Ersekerci E; Sofikerim M; Taheri S; Demirtas A; Halis F
    Genet Mol Res; 2015 Jul; 14(3):7326-34. PubMed ID: 26214411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.